广东省重组人凝血因子Ⅷ药物评价与遴选专家共识.

Recombinant human coagulation factor Ⅷ is the first-line treatment for hemophilia A recommended by authoritative guidelines. Various recombinant human coagulation factor Ⅷ have the same mechanism of action, which can temporarily replace the missing clotting factor Ⅷ that is needed for effective hemostasis in patients. There are differences in economy, pharmaceutical characteristics and other attributes. Therefore, pharmaceutical and clinical experts are organized by the Pharmacovigilance Professional Committee of Guangdong Pharmaceutical Association to formulate the Expert Consensus on Evaluation and Selection of Recombinant Human Coagulation Factor Ⅷ in Guangdong. Multi-dimensional evaluation on 6 kinds of recombinant human coagulation factor Ⅷ marketed in China are carried out from five aspects: pharmaceutical characteristics, efficacy, safety, economy and other attributes, so as to provide scientific basis for drug selection in medical institutions and promotes rational drug use in clinic. [ABSTRACT FROM AUTHOR]